The mission of the OSUCCC Clinical Treatment Unit and Clinical Trials Processing Laboratory Shared Resource (CTU/CTPL SR) is to advance the quality and efficiency of early phase clinical translational research. The CTU/CTPL SR is a new shared resource but has been in development since January 2004 when it was created to support and expand our ability to conduct early Phase I and II clinical trials. The CTU/CTPL SR is composed of two different but intimately related units: the Clinical Treatment Unit (CTU) and the Clinical Trials Processing Laboratory (CTPL). Historically, the CTU/CTPL SR has been funded solely with OSUCCC/institutional support. The CCSG will only support the CTPL component of the SR. The CTU is a $2 M ambulatory """"""""phase 1 unit"""""""" constructed in The James Cancer Hospital in 2004. The CTU specializes in treating cancer patients on early clinical trials requiring intense monitoring and/or complex correlative specimen collection and processing. The CTPL enhances the quality of research by providing dedicated staff for high volume procurement, processing, storage, delivery, and shipment of research specimens critical to the correlative studies component of OSUCCC clinical trials. Highly trained staff in the CTU/CTPL SR works closely with the Clinical Trials Office (CTO), Pharmacoanalytical (PhASR), Leukemia Tissue Bank (LTBSR) and Biorepository and Biospecimen (BBR) Shared Resources to provide protocol review and feasibility assessment, specimen kit assembly and distribution of specimens to internal and external research laboratories. The infrastructure of the OSUCCC CTU/CTPL SR is well established and is directly under CCC leadership. Larry Schaaf, Ph.D., Director of the Resource brings a wealth of experience to the CTU/CTPL SR with over 20 years of experience in conducting and analyzing phase I clinical correlative trials and over 55 publications. The CTU/CTPL SR has been widely used by the OSUCCC clinical research community since its inception in 2004. During this time period, the CTU has supported 83 protocols involving >850 patients and more than 10,400 patient visits and the CTPL has procured and/or processed over 35,200 patient specimens. During the past year, 21 OSUCCC members have utilized the CTU/CTPL SR for 90 projects, representing 5 of the 6 OSUCCC programs and making up 80.3% of the overall CTU/CTPL SR usage, with the remainder being utilized by clinical oncology faculty who work directly with or for OSUCCC members. An additional 41 new protocols have been identified for future support In the first half of coming year. This Shared Resource will continue to enhance the quality of clinical translational research conducted at the OSUCCC by providing improved efficiency, enhanced compliance, and cost-effective centralized support of eerily phase correlative studies.

Public Health Relevance

The Ohio State University Comprehensive Cancer Center (OSUCCC) Clinical Treatment Unit/Clinical Trials Processing Laboratory Shared Resource (CTU/CTPL SR) provides a stable, reliable, and cost-effective,state-of-the art unit for conducting eariy phase clinical trials requiring intense monitoring and/or complex correlative specimen collection. It also provides high quality, high volume specimen processing, short-term storage and distribution of liquid specimens for pharmacokinetics or other biomarkers collected as correlative components of phase I and II translational clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601814
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$169,433
Indirect Cost
$58,330
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Suarez-Kelly, Lorena P; Akagi, Keiko; Reeser, Julie W et al. (2018) Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity. Cold Spring Harb Mol Case Stud 4:
Malpeli, Giorgio; Barbi, Stefano; Greco, Corinna et al. (2018) MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. Oncotarget 9:19961-19979
Talbert, Erin E; Lewis, Heather L; Farren, Matthew R et al. (2018) Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. J Cachexia Sarcopenia Muscle 9:358-368
Wang, Jin-Ting; Xie, Wen-Quan; Liu, Fa-Quan et al. (2018) NADH protect against radiation enteritis by enhancing autophagy and inhibiting inflammation through PI3K/AKT pathway. Am J Transl Res 10:1713-1721
Karpurapu, Manjula; Lee, Yong Gyu; Qian, Ziqing et al. (2018) Inhibition of nuclear factor of activated T cells (NFAT) c3 activation attenuates acute lung injury and pulmonary edema in murine models of sepsis. Oncotarget 9:10606-10620
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Tasselli, Giorgia; Filippucci, Sara; Borsella, Elisabetta et al. (2018) Yeast lipids from cardoon stalks, stranded driftwood and olive tree pruning residues as possible extra sources of oils for producing biofuels and biochemicals. Biotechnol Biofuels 11:147
Moliva, J I; Hossfeld, A P; Canan, C H et al. (2018) Exposure to human alveolar lining fluid enhances Mycobacterium bovis BCG vaccine efficacy against Mycobacterium tuberculosis infection in a CD8+ T-cell-dependent manner. Mucosal Immunol 11:968-978
Fu, Qiang; Chen, Mingqing; Hu, Shuiying et al. (2018) Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 1090:43-51

Showing the most recent 10 out of 2602 publications